351 related articles for article (PubMed ID: 21118093)
1. The challenge of exploiting ABCG2 in the clinic.
Robey RW; Ierano C; Zhan Z; Bates SE
Curr Pharm Biotechnol; 2011 Apr; 12(4):595-608. PubMed ID: 21118093
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
3. ABCG2: structure, function and role in drug response.
Polgar O; Robey RW; Bates SE
Expert Opin Drug Metab Toxicol; 2008 Jan; 4(1):1-15. PubMed ID: 18370855
[TBL] [Abstract][Full Text] [Related]
4. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
5. ABCG2: a perspective.
Robey RW; To KK; Polgar O; Dohse M; Fetsch P; Dean M; Bates SE
Adv Drug Deliv Rev; 2009 Jan; 61(1):3-13. PubMed ID: 19135109
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
7. Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.
Deeken JF; Robey RW; Shukla S; Steadman K; Chakraborty AR; Poonkuzhali B; Schuetz EG; Holbeck S; Ambudkar SV; Bates SE
Mol Pharmacol; 2009 Nov; 76(5):946-56. PubMed ID: 19633067
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
10. Molecular pharmacology of ABCG2 and its role in chemoresistance.
Stacy AE; Jansson PJ; Richardson DR
Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
[TBL] [Abstract][Full Text] [Related]
11. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
12. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
Hardwick LJ; Velamakanni S; van Veen HW
Br J Pharmacol; 2007 May; 151(2):163-74. PubMed ID: 17375082
[TBL] [Abstract][Full Text] [Related]
13. ABCG2: determining its relevance in clinical drug resistance.
Robey RW; Polgar O; Deeken J; To KW; Bates SE
Cancer Metastasis Rev; 2007 Mar; 26(1):39-57. PubMed ID: 17323127
[TBL] [Abstract][Full Text] [Related]
14. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Natarajan K; Xie Y; Baer MR; Ross DD
Biochem Pharmacol; 2012 Apr; 83(8):1084-103. PubMed ID: 22248732
[TBL] [Abstract][Full Text] [Related]
15. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.
Xia CQ; Yang JJ; Gan LS
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):595-611. PubMed ID: 16863427
[TBL] [Abstract][Full Text] [Related]
17. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic importance of ABCG2.
Cusatis G; Sparreboom A
Pharmacogenomics; 2008 Aug; 9(8):1005-9. PubMed ID: 18681776
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
Ejendal KF; Hrycyna CA
Curr Protein Pept Sci; 2002 Oct; 3(5):503-11. PubMed ID: 12369998
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
